Skip to content

Research at St Andrews

Profiling persistent tubercule bacilli from patient sputa during therapy predicts early drug efficacy

Research output: Contribution to journalArticle

Author(s)

Isobella Honeyborne, Timothy D. McHugh, Iitu Kuittinen, Anna Cichonska, Dimitrios Evangelopoulos, Katharina Ronacher, Paul D. van Helden, Stephen H. Gillespie, Delmiro Fernandez-Reyes, Gerhard Walzl, Juho Rousu, Philip D. Butcher, Simon J. Waddell

School/Research organisations

Abstract

Background. New treatment options are needed to maintain and improve therapy for tuberculosis, which caused the death of 1.5 million people in 2013 despite potential for an 86 % treatment success rate. A greater understanding of Mycobacterium tuberculosis (M.tb) bacilli that persist through drug therapy will aid drug development programs. Predictive biomarkers for treatment efficacy are also a research priority.
Methods and Results. Genome-wide transcriptional profiling was used to map the mRNA signatures of M.tb from the sputa of 15 patients before and 3, 7 and 14 days after the start of standard regimen drug treatment. The mRNA profiles of bacilli through the first 2 weeks of therapy reflected drug activity at 3 days with transcriptional signatures at days 7 and 14 consistent with reduced M.tb metabolic activity similar to the profile of pre-chemotherapy bacilli. These results suggest that a pre-existing drug-tolerant M.tb population dominates sputum before and after early drug treatment, and that the mRNA signature at day 3 marks the killing of a drug-sensitive sub-population of bacilli. Modelling patient indices of disease severity with bacterial gene expression patterns demonstrated that both microbiological and clinical parameters were reflected in the divergent M.tb responses and provided evidence that factors such as bacterial load and disease pathology influence the host-pathogen interplay and the phenotypic state of bacilli. Transcriptional signatures were also defined that predicted measures of early treatment success (rate of decline in bacterial load over 3 days, TB test positivity at 2 months, and bacterial load at 2 months).
Conclusions. This study defines the transcriptional signature of M.tb bacilli that have been expectorated in sputum after two weeks of drug therapy, characterizing the phenotypic state of bacilli that persist through treatment. We demonstrate that variability in clinical manifestations of disease are detectable in bacterial sputa signatures, and that the changing M.tb mRNA profiles 0–2 weeks into chemotherapy predict the efficacy of treatment 6 weeks later. These observations advocate assaying dynamic bacterial phenotypes through drug therapy as biomarkers for treatment success.
Close

Details

Original languageEnglish
Pages (from-to)1-13
Number of pages13
JournalBMC Medicine
Volume14
Issue number1
DOIs
StatePublished - 7 Apr 2016

    Research areas

  • Mycobacterium tuberculosis, Sputum, Transcriptional profiling, Predictive biomarker, Persistent infection

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Centrifugation and decontamination procedures selectively impair recovery of important populations in Mycobacterium smegmatis

    Kennedy, J. A., Baron, V. O., Hammond, R. J. H., Sloan, D. J. & Gillespie, S. H. 1 Aug 2018 In : Tuberculosis.

    Research output: Contribution to journalArticle

  2. Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Crook, A. M., Amukoye, E. I., Dawson, R., Diacon, A. H., Hanekom, M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murphy, M. E., Murthy, S. E., Nunn, A. J., Phillips, P. P. J., Singh, K. P., Spigelman, M., Wills, G. H. & Gillespie, S. H. 11 Jul 2018 In : BMC Infectious Diseases. 18, 11 p., 317

    Research output: Contribution to journalArticle

  3. Moxifloxacin replacement in contemporary tuberculosis drug regimens is ineffective against persistent Mycobacterium tuberculosis: in the Cornell mouse model

    Liu, Y., Pertinez, H., Davies, G. R., Gillespie, S. H., Coates, A. R. & Hu, Y. Jul 2018 In : Antimicrobial Agents and Chemotherapy. 62, 7, 9 p., e00190-18

    Research output: Contribution to journalArticle

  4. Forecasting clinical dose-response from pre-clinical studies in tuberculosis research - translational predictions with rifampicin

    Wicha, S. G., Clewe, O., Svensson, R. J., Gillespie, S. H., Hu, Y., Coates, A. R. M. & Simonsson, U. S. H. 19 Jun 2018 In : Clinical Pharmacology & Therapeutics. Early View

    Research output: Contribution to journalArticle

  5. The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis

    Svensson, E. M., Svensson, R. J., Te Brake, L. H. M., Boeree, M. J., Heinrich, N., Konsten, S., Churchyard, G., Dawson, R., Diacon, A. H., Kibiki, G. S., Minja, L. T., Ntingiya, N. E., Sanne, I., Gillespie, S. H., Hoelscher, M., Phillips, P. P. J., Simonsson, U. S. H. & Aarnoutse, R. 18 Jun 2018 In : Clinical Infectious Diseases. 67, 1, p. 34-41 8 p.

    Research output: Contribution to journalArticle

Related by journal

  1. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study

    Tweed, C. D., Wills, G. H., Crook, A. M., Dawson, R., Diacon, A. H., Louw, C. E., McHugh, T. D., Mendel, C., Meredith, S., Mohapi, L., Murphy, M. E., Murray, S., Murthy, S., Nunn, A. J., Phillips, P. P. J., Singh, K., Spigelman, M. & Gillespie, S. H. 28 Mar 2018 In : BMC Medicine. 16, 10 p., 46

    Research output: Contribution to journalArticle

  2. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis

    Murthy, S. E., Chatterjee, F., Crook, A., Dawson, R., Mendel, C., Murphy, M. E., Murray, S. R., Nunn, A. J., Phillips, P. P. J., Singh, K. P., McHugh, T. D., Gillespie, S. H. & REMoxTB Consortium 21 May 2018 In : BMC Medicine. 16, 11 p., 73

    Research output: Contribution to journalArticle

  3. A comparison of liquid and solid culture for determining relapse and durable cure in phase III TB trials for new regimens

    Phillips, P. P. J., Mendel, C. M., Nunn, A. J., McHugh, T. D., Crook, A. M., Hunt, R., Bateson, A. & Gillespie, S. H. 24 Nov 2017 In : BMC Medicine. 15, 9 p., 207

    Research output: Contribution to journalArticle

  4. Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

    Lubbock, A. L. R., Stewart, G. D., O'Mahoney, F. C., Laird, A., Mullen, P., O'Donnell, M., Powles, T., Harrison, D. J. & Overton, I. M. 26 Jun 2017 In : BMC Medicine. 15, 12 p., 118

    Research output: Contribution to journalArticle

  5. Spot sputum samples are at least as good as early morning samples for identifying Mycobacterium tuberculosis

    Murphy, M. E., Phillips, P. P. J., Mendel, C. M., Bongard, E., Bateson, A. L. C., Hunt, R., Murthy, S., Singh, K. P., Brown, M., Crook, A. M., Nunn, A. J., Meredith, S. K., Lipman, M., McHugh, T. D., Gillespie, S. H. & REMoxTB Consortium 27 Oct 2017 In : BMC Medicine. 15, 10 p., 192

    Research output: Contribution to journalArticle

ID: 242220926